Introduction
Cholecalciferol (vitamin D3) is converted in the liver to 25- hydroxycholecalciferol, the main circulating form of vitamin D. ' 2 Further hydroxylation in the 1-a-position to 1-ax, 25- dihydroxycholecalciferol (1-,x, 25 -(OH)2D,) occurs in the kidney.3 In patients with renal failure, in whom the production of 1-ox, 25-(OH)2D4 is impaired,' its administration increases calcium absorption and raises levels of plasma calcium and phosphate.5 1-x, 25-(OH)2D, has also been shown to heal renal osteodystrophy and improve associated muscle weakness. 6 1-ca-Hydroxycholecalciferol (1-ce-OHD3) is more easily synthesised than 1-xc, 25-(OH),D, and may be converted to 1-ce, 25-(OH)2D, in the intact organism. Large doses of 1-x-OHD3 (10-30 jsg/day) given to patients with renal failure resulted in great increases in 47Ca absorption and serum calcium levels.9 10 Smaller doses of 1-ac-OHD, ( 2 /sg/day) used for short periods in three dialysed patients were associated with significant increases of intestinal calcium absorption and calcium content of the hand assessed by regional neutron activation analysis. '1 More prolonged courses of treatment with 1-c-OHD3 (0-5-10 1kg/day) in three adolescents with renal bone disease not undergoing dialysis resulted in clinical, biochemical, and radiological improvements and a rise in bone mineral content. ' 2 In further studies"3 ' treatment with 1-ac, 25-(OH)2D3 and 1-ac-OHD3 for up to 12 months in both children and adults reversed the clinical, biochemical, radiological, and histological manifestations of renal osteodystrophy in children. In adults the effects were less consistent and hypercalcaemia was more common.
We have measured the changes in whole-body calcium assessed by neutron activation analysis during treatment with 1-oc-OHD3 in selected patients with renal osteodystrophy and related these changes to the biochemical, radiological, and histological responses.
Patients and methods
Four adult patients (table I) treated with intermittent dialysis for chronic renal failure (Cordis Dow or Kiil dialyser for 20-30 hours a week) were studied. All patients had symptomatic renal bone disease and represented the range of renal osteodystrophy seen in this renal unit. None had received vitamin D supplements. The composition of the dialysis fluid was unaltered during the course of the study (calcium 1 6 mmol/1 (0 8 mEq/1), magnesium 0 4 mmol/1 (0 2 mEq/1); in case 4 calcium was 2 0 mmol/1 (1 0 mEq/1)).
BRITISH MEDICAL JOURNAL 10 JULY 1976 phosphatase was measured by the LKB reaction rate analyser with xe-napthyl phosphate as substrate. 18 Bone alkaline phosphatase isoenzyme fraction was determined by using heat stability and L-phenylalanine inhibition techniques.'9 (The normal adult range for alkaline phosphatase is 17-75 IU/11 and for bone alkaline phosphatase 0-30 IU/I). Parathyroid hormone (PTH) was measured by radioimmunoassay using an antiserum (GP-1) which reacts predominantly to the amino-terminal region of the molecule2" (normal level < 0 2 ug/l).
Transiliac bone biopsies were performed under local anaesthesia before and four to five months after the start of treatment.
1-a-OHD3 2 tg daily was given by mouth. Treatment was continued for 10-12 months, though the doses were adjusted (see fig 1) . At the start of treatment the patients also took a daily supplement of 1 g calcium as the gluconate. Three patients (cases 1-3) did not receive aluminium hydroxide gel during the period of study but the other was given aluminium hydroxide for pruritus seven months after the start of treatment, without relief.
Results
Symptoms-Bone pain was reduced and muscle power improved in cases 1 and 2 (table I). In case 3 treatment was associated with increased stiffness and no reduction in bone pain, and in case 4 bone pain did not improve and pruritus increased.
Biochemical results-Plasma calcium levels rose in three patients, and in case 3 treatment was stopped because of symptomatic hypercalcaemia ( fig 1) . Calcium levels fell thereafter though not to pretreatment levels. The patient probably continued to take 1-cx-OHD3.
No consistent changes were seen in plasma phosphate levels. Plasma PTH levels decreased during treatment though they did not fall to normal. 4 Whole-body calcium was estimated every four to six months by whole-body neutron activation analysis.'-The coefficient of variation in control patients using t4is method is 300. Calcium absorption was assessed using a whole-body counter to measure the retention at seven days of an oral dose of about 5 CCi o given in 200 mg of calcium as the chloride." ' Plasma calcium, ionised calcium, and inorganic phosphate were measured as previously described. ' Blood samples for biochemical estimations were collected during the 12 hours before a dialysis. (Normal ranges are: inorganic phosphate 0 80-1*45 mmol/l (2 5-4-5 mg/100 ml); plasma calcium 2 33-2 60 mmol/l (9 3-10 4 mg/100 ml); ionised calcium 0-93-1 17 mmol/l (3 7-4 7 mg/100 ml). The coefficient of variation for ionised calcium was 240°,.) Activity of alkaline Total body calcium-There were significant increases of total body calcium in cases 1 and 2 after treatment ( fig 2) . In the two patients in whom there were no decreases in alkaline phosphatase (cases 3 and 4;
fig 2) 
Discussion
The use of 1-c-OHD, in metabolic bone disease may be associated with increased mineralisation," 22 but the drug is healing in the ilium was slow compared with that in other areas and that the interval between biopsies (four to five months) was too brief to observe a maximal effect of 1-o-OHD3 or that the ivcrease in total body calcium was due to an increase in soft tissue calcification. The latter possibility seems less likely in view of the large increments of total body calcium seen in our patients and the absence of any evidence of ectopic calcification. Though large doses of calcium carbonate and calcium phosphate (5-10 g/day) improve calcium and phosphate balance in uraemic patients with chronic renal failure,26 our patients were, in contrast, given modest doses of calcium with 1-oc-OHD3 to supplement their diet. The responses observed were unlikely, therefore, to reflect a response to calcium supplements alone but could be reasonably ascribed to an effect of 1-m-OHD3.
Two patients (cases 1 and 2) showed initial increases in ionised calcium during 1--OHD3 treatment without an associated rise in total calcium, and another patient (case 4), who remained hypercalcaemic, showed a fall in ionised calcium. In view of the low coefficient of variation of the method ofmeasuring ionised calcium, these changes probably reflect changes of protein binding which, in turn, may have been dependent on changes of pH, 1-m-OHD3, or the dialysis procedure.17
If ionised calcium is the primary means by which PTH output is regulated,27 28 it seems reasonable to suppose that the suppression of PTH secretion with 1-m-OHD3 in cases 1 and 2 was associated with an increase in plasma concentration of ionised calcium. In the other patients there was no measurable increase in ionised calcium, and direct inhibition of PTH secretion by the vitamin D analogue may provide an alternative mechanism.29
It is not clear why the other two patients (cases 3 and 4; figs 3 and 4) showed poor responses to treatment. One (case 3) showed several features that suggested progression of bone disease; his symptoms increased, radiological features deteriorated, and there was a loss of whole-body calcium. Although this loss may have been related to the progressive demineralisation seen in some patients on chronic haemodialysis,'5 1-cx-OHD, may, by increasing bone resorption, have contributed to the deterioration of renal bone disease. The plasma calcium did not fall to pretreatment levels despite stopping 1-a-OHD,. The prompt fall of plasma calcium to pretreatment levels in other patients with hypercalcaemiall 12 suggests that self-medication was responsible for the continuing hypercalcaemia in our patient.
The discriminatory value of total alkaline phosphatase activity may be limited in renal osteodystrophy,30 31 and measurement of the bone isoenzyme may provide a more useful index of bone disease, particularly in its early stages. 19 In case 3 the total activity of alkaline phosphatase was normal before treatment, increased, and then fell during treatment with 1-01-OHD, (fig 1) . In contrast, the bone-derived alkaline phosphatase level was raised before 1-o-OHD3 and increased further during treatment. The activity of bone-derived plasma alkaline phosphatase was raised before treatment in case 2, although total plasma alkaline phosphatase was normal. Treatment was followed by a more rapid fall of bone phosphatase than total alkaline phosphatase and the latter was obscured in part by a rise of the liver isoenzyme. These observations suggest that measurement of the bone isoenzyme may also be useful in assessing the response to treatment. taining vitamin 1-K-dependent clotting factors has offered a possible means of reversing the coumarin defect with small volumes of infusate containing large quantities of clotting factors. A great potential hazard of using these concentrates in patients with recently established thrombosis is, however, the production of disseminated intravascular coagulation (DIC). Reports of the safe use of the concentrates in treating Christmas disease' and liver disease2 3 has prompted this study, in which the effectiveness of a prothrombin complex concentrate and vitamin K1 in reversing oral anticoagulant overdosage were compared. A product containing factors II, IX, and X only (ProthromplexImmuno; Serological Products Ltd, Dunton Green, Kent) was studied as it is the type of preparation generally available.4
Methods
Eighteen instances of overdoses with nicoumalone (Sinthrome) and two with warfarin were studied. Patients with a British ratio over 5 0 were randomised into two groups. Group 1 (nine patients) received 2 5 mg vitamin K, intravenously, while group 2 (nine patients) received the concentrate intravenously over 10 minutes, the doses of concentrate varying from 4 7 to 16 units/kg body weight with a mean dose of 12 units/kg. The concentrate contained 0 01-0 05 IU heparin/ unit of factor II. Blood pressure, pulse, and temperature were observed every 15 minutes for one hour after infusion. In both groups blood specimens were taken before and half an hour, two hours, and 24 hours after infusion. No oral anticoagulants were given for 24 hours after infusion.
Laboratory tests-Full blood count; platelet count; measurements of prothrombin time (using British comparative thromboplastin) and partial thromboplastin time (using the proposed international partial thromboplastin time reference preparation); specific assays for factors II, VII, and X; and measurements of thrombin time, fibrinogen, and fibrinogen degradation products (FDP) (by haemagglutination inhibition assay using human red blood cells) were performed on all specimens. Patients receiving the concentrate were screened for the presence of hepatitis B surface antibody (HBsAb) and antigen (HBsAg) before infusion and every month, when possible, for at least six months. (HBsAb and HBsAg were detected by passive haemagglutination.)
Results PROTHROMBIN TIME Group 1-All patients receiving vitamin K, showed reversal of the anticoagulant defect, but at 30 minutes there was no appreciable
